²Ä¤T³¹ ¯×½è              ¤ý»ñ­^

²Ä¤T³¹ ¯×½è

²Ä¤@¸`_¯×½è¤§¯S©Ê
²Ä¤G¸`_¯×½è¤ÀÃþ
²Ä¤T¸`_¯×½è¤§®ø¤Æ¡B§l¦¬»P¥NÁÂ
²Ä¥|¸`_¯×½èªº»Ý­n¶q
²Ä¤­¸`_¯×½è»P¤ß¦åºÞ¯e¯f¯×½è¤§¯Ê¥F¯g
¤pÀɮסGOmega-3¯×ªÕ»Ä
°Ñ¦Ò¤åÄm

¤pÀɮסGOmega-3¯×ªÕ»Ä¡B¤¤Ãì¯×ªÕ»Ä¡]MCT¡^

¯×½è¡]Lipid¡^¡G¥]¬A¡G¯×ªÕ¡]Fats¡^»Pªo¯×¡]Oil¡^¡C¥ÑºÒ¡B²B¤Î®ñ©Ò²Õ¦¨¡A¤£·»©ó¤ô¡A¥i·»©ó¦³¾÷·»¾¯¦p¤Aîũδâ¥é¡A¼sªxªº¦s¦b©ó¥Í©RÅ餤¡A¦p¡G´Óª«ªo¡B¥¤ªo¡B½Þªo¡B¤ûªo»Pþµ¥¯×½è¡C¬°¨­Å餧¥D­n¦¨¤À¡A¬°¨Ñµ¹¯à¶q¡A¥Ö¤U¯×ªÕ¬°¹j¼ö¡A¨¾¤î¼ö¯à´²¥¢¡A«OÅ@¾¹©x¡A«OÅ@¯«¸g¶Ç¾É¥¿±`¡A¯×½è¦³µ´½t¤§§@¥Î¡A«P¶i²Ó­Mªº¥NÁ¡A¨Ñµ¹¥²»Ý¯×ªÕ»Ä¡A¦³¼W¥[¹¡­¹·P»P¼í·ÆÁT«K¤§¥\¯à¡C

²Ä¤@¸` ¯×½è¤§¯S©Ê     [top]

¤@¡B ªo¯×ªº¥\¯à

1. ´£¨Ñ¯à¶q¡G¯×ªÕ»Ä´£¨Ñ¤F60%¤HÅé©Ò»Ý¼ö¶q¡A¦Ù¦×©Ò»Ý­nªº¯à¶q¥D­n¨Ó¦Û¶¼­¹Äá¨úªºªo¯×»PÁÞÃþ©M¯×ªÕ²Õ´Àx¦sªº¯×ªÕ»Ä¡C¦b°¨©ÔªQ©Î¦Û¥Ñ¨®µ¥­@¤O¹B°Ê¤¤¡A°£¤F¯×ªÕ»Ä¤§¿U¿N´£¨Ñ¦Ù¦×¨Ï¥Î¥~¡A¤]¦³¤j¶qªºÁÞÃþ°Ñ»P¡C¤HÅé²Õ´»Ý­n¯×ªÕ»Ä¨Ó´£¨Ñ¼ö¶q¡C¦]¦¹¡Aªo¯×»PÁÞÃþ¤@¼Ë§¡¯à´£¨Ñ¯à¶q¡A³£¦³«OÅ@Å餺³J¥Õ½èªº®ÄÀ³¡A¥iÁ×§KÅé²Õ´ªº¯Ó·l¡C¤T¥Ìªoà­¡}Triglycerides¡~¨C¤½§J¥i¥H²£¥Í9¤j¥d¼ö¶q¡A¤ñ³J¥Õ½è©ÎÁÞÃþ¥u¯à²£¥Í4¤j¥d¡Aªo¯×´£¨Ñ¯à¶qªº®Ä²v°ª«Ü¦h¡C

2. Àx¦s¼ö¶q¡G¤HÅé¥H¯×ªÕªº§Î¦¡Àx¦s¯à¶q¡AÀx¦sªo¯×ªº²Ó­MºÙ¬°¯×ªÕ²Ó­M¡}Adipocytes¡~¡A¤j¶qªº¯×ªÕ²Ó­M§Î¦¨¯×ªÕ²Õ´¡}Adipose tissue¡~¡C¦p¤k©Ê¯Ý³¡»PÁv³¡¯×ªÕ¸û¦h¡A¥i¥H¨ÑÃh¥¥©M­÷¨Å´Áªº§Q¥Î¡C¦pªG¼ö¶qÀx¦s¦b¦Ù¦×²Õ´¤¤¡A«h·|¤@¨ÖÀx¦s³\¦h¤ô¥÷¡Aª½±µ¥H¯×ªÕ¥u»Ý¸û¤Ö¯à¶q´N¯àÀx¦s¡C

3. ¹jµ´»P«OÅ@§@¥Î¡G¯×ªÕ²Õ´ªº­«¶q¤j¬ù¦ûÅé­«ªº15-30%¡C¤ºÅ¦¯×ªÕ¦s¦b­«­nªº¤ºÅ¦¾¹©x¡]¨Ò¦pµÇŦ¡^¥~¼h¡A¯à¨¾¾_©M´î¤Ö¾¹©x¶Ë®`¡C¤k©Êªº¯Ý³¡»PÁv³¡¯×ªÕ¸û¦h¡A¦³«OÅ@¥Í´Þ¾¹©xªº¥\¥Î¡C¥Ö¤U¯×ªÕ²Õ´¦s¦b¥Ö½§¯u¥Ö©³¤U¡A¥i¥H¹jµ´©M«OÅ@¾¹©x§K©ó¨ü¶Ë¡C¯×ªÕ²Õ´ªº¹jµ´¡B«OÅ@»PŨ¹Ôªº¥\¯à¡A¥i¥H´î¤Ö¬¡°Ê®Éªº¯kµh¤Î¥Ö½§¹ï§C·Åªº½Õ¾A±Ó·P¡C¦p´H±a°Êª«¹³¥_·¥ºµ¡B®ü°\©MÄH³½³£¦³¤j¶q¯×ªÕ²Õ´¡A¥H¹jµ´´H§NªºÀô¹Ò¡C

4. ¹B°e¯×·»©Êºû¥Í¯À¡G¯×ªÕ¯àÄâ±a­¹ª«¤¤ªºªo·»©Êºû¥Í¯À¡]A¡AD¡AE©MK¡^¶i¤J¤p¸z¡A¥H§Q§l¦¬¡C·í¸z¹D¥Í¯f®É¡A«hµLªk®ø¤Æ§l¦¬¯×ªÕ¡A¯×·»©Êºû¥Í¯À´N·|©M¯×ªÕ¶i¤J¤j¸z¡A©MÁT«K¤@°_±Æ¥XÅé¥~¡C¯×ªÕ§l¦¬¤£¨}ªº¤H¡A¥i¯à·|¯Ê¥F¯×·»©Êºû¥Í¯À¡]¤×¨ä¬OK¡^¡C¦]¦¹¡A´î¤Ö­¹«~¤¤ªºªo¯×§t¶q¡A¦P®É¤]´î¤Ö¯×·»©Êºû¥Í¯Àªº§t¶q¡A¦p¡G§C¯×¥¤¡B²æ¯×¥¤µ¥¡C

5. ´£¨Ñ¥²»Ý¯×ªÕ»Ä¡G¨Èªo»Ä¡]Linoleic acid¡^»Pn-3¨t¦C¯×ªÕ»Ä¡A¥Î©ó¦X¦¨¤G¤QºÒ²m»Ä±Ú¦¨¤Àµ¥²£ª«¡A»P²üº¸»XÃþ¦ü¨ã¦³½Õ¸`¥Í²zªº§@¥Î¡C·í¯Ê¥F¥²»Ý¯×ªÕ»Ä·|¨Ï¥Ö½§µ²ºc¨ü¶Ë¡A®e©ö¥¢¥h¤ô¤À¦Ó°®Àê¡C

6. ºc³y»P½Õ¸`§@¥Î¡GÁC¯×½è©MÁx©T¾J¦b¤HÅ餺¦³­«­nªº¥Í²z¥\¯à¡CÁC¯×½è¬Oºc¦¨²Ó­M½¤¤§¦¨¥÷¡A¤]¬O¦å²G¤¤¯×³J¥Õªº­«­n¦¨¤À¡A¨ó§U¯×ªÕªº¹B°e¡C¦b­¹ª«¤¤¡AÁC¯×½è¥i¥H§@¬°¨Å¤Æ¾¯¡A«P¶i¤ô¤À»Pªo¯×ªº¤¬·»©M¦w©w©Ê¡CÁx©T¾J¤]¬O²Ó­M½¤ªº¦¨¤À¡A¸£³¡§t¶q«Ü¦h¡A¥À¥¤¤¤ªº§t¶q°ª¡A¹ï©ó¥Íªø»Pµo¨|¤]¬O«Ü­«­n¡CÁx©T¾J©óÅ餺¯à¦X¦¨ÁxÆQ¡Bºû¥Í¯À¢Ò»P©T¾JÃþ¿E¯Àµ¥¡C

7. ´£¨Ñ¹¡¨¬·P¡G¯×½è¨Ï­¹ª«¦b­G°±¯d±o¤ñ¸û¤[¡A´£¨Ñ¤F¹¡¨¬·P¡C¦pªG­¹ª«¤j³¡¥÷¬OÁÞÃþ©Î³J¥Õ½è¡A°±¯d¦b­Gªº®É¶¡´N¤ñ¸ûµu¡C¤Ö¦Yªo¯×¡A´N·|¥¢¥h¹¡¨¬·P¦Ó«Ü®e©ö´N¾j¤F¡C

8. ´£¨Ñ­¹ª«­·¨ý©M½è·P¡GµuÃ쪺¯×ªÕ»Ä¯àµo´§¥XªÚ­»­»®ð¡A¦³³\¦h­»®Æ¬O¯×·»©Êªº¡A¦Ó¥Bªo¯×¥i¥H¥[¼ö¨ì200¢J¡Aªo·Î©Îªo¬µ¨Ï­¹ª«§Ö³t¥[¼ö¡AÁYµu²i½Õªº®É¶¡¦Ó«O¯d§ó¦hªº­·¨ý¡A©ñ¦bªo¸Ìªº½Õ¨ý®Æ¥i¯à·|´²µo¥X¿@­§ªº­»¨ý¡C¦U¦¡ªº¬ü¨ý¨ÎÀa¡A³£¦³°ªªoªº¯S©Ê¡A³oºØªo¯×ªº­·¨ý¬O¤HÃþ¦@¦P³ß¦nªº¯S©Ê¡C

¤G¡B ªo¯×¤§¤Æ¾Ç²Õ¦¨ ¡G

ªo¯×ªººc³y³æ¦ì¡G¯×ªÕ»Äªº°ò¥»ºc³y¡G¥D­n¬OºÒ¡A²B¡A®ñ¤¸¯Àºc¦¨¡C¤À¤lªº°©¬[¬O¥ÑºÒ­ì¤l¦ê³s¦Ó¦¨¡AºÒ¤¸¯À¥HC¥Nªí¡A¤@ºÝ¬°¥Ò°ò¡]CH3-¡^¡A¥t¤@ºÝ¬°»Ä¡]-COOH¡^¡AºÒ­ì¤l¤§¶¡¥H¦@»ùÁä¦êÁp¡A¤¤¶¡ªººÒ­ì¤l¤W³£³s±µ¦³¨â­Ó²B­ì¤l¡C¥Ò°òºÝ¤]ºÙ¬° n ºÝ©Î £s ºÝ¡A»Ä°òºÝ¤SºÙ¬° £\ ºÝ¡C¶¼­¹¤¤¤§ªo¯×¥H¤T»Ä¥Ìªoà­¬°¥D¡A¦û95¢M¥H¤W¡C°ò¥»¤Æ¾Çµ²ºc¬O¤@¤À¤l¥Ìªo¡]Glycerol¡^»P¤T¤À¤l¯×ªÕ»Ä(Fatty acids)¤Æ¦X¡Cªo¯×ªº¯S©Ê¨ú¨M©ó©Ò§tªº¯×ªÕ»Ä¡A¦]¬°¦UºØªo¯×³£§t¦³¥Ìªo¡C

1. ²³æ¯×½è¡G¥Ìªo»P¯×ªÕ»Äºc¦¨ªºªo¯×¡C¦p¡G¤T»Ä¥Ìªo¯×§t¦³¤@¤À¤l¥Ìªo»P¤T­Ó¯×ªÕ»Ä¤À¤l¡C






¹Ï3-1. ¤T»Ä¥Ìªo¯×»P¯×ªÕ»Äºc¦¨ªºªo¯×

2. ½Æ¯×Ãþ¡G§t¥Ìªo¡B¯×ªÕ»Ä¡BÁC»Ä®Ú»PÆQ°ò¡C
¦p¡GÁC¯×½è§t¦³¤@¤À¤l¥Ìªo¡B¨â¤À¤l¯×ªÕ»Ä¡B¤@¤À¤lÁC»Ä®Ú¡B¤@¤À¤lÁxÆP¡C













¹Ï3-2. ½Æ¯×Ãþ¡G§t¥Ìªo¡B¯×ªÕ»Ä¡BÁC»Ä®Ú»PÆQ°ò

3. ­l¯×Ãþ¡G¤£§t¥Ìªoªº¯×½è¡A¨Ò¦pÁx©T¾J¡C¤HÅ餧¯×½è¤S¤À¬°¤º¥Í©Ê¡]¬°Å餺¤º³¡²Õ´¤§¤@¡^¤Î¥~¥Í©Ê¡]¥Ñ­¹ª«¤¤¤§°Êª«ªo¯×»P´Óª«ªo¡^¡C¥D­n¬°¤T»Ä¥Ìªoà­§Y¤@¤À¤l¤§¥Ìªo¤Î¤T¤À¤l¤§¯×ªÕ»Ä¡C









¹Ï3-3. ¤£§t¥Ìªoªº¯×½è¡A¦pÁx©T¾J

¤T¡B¯×ªÕ»Äªº¤Æ¾Ç§@¥Î¡G


²B¤Æ§@¥Î¡]Hydrogenation¡^¡G¤£¹¡©M¯×ªÕ»Ä»P²Bªº¤Æ¾Ç§@¥Î¡A¨Ï±o¤£¹¡©MªºÂùÁä¡}C=C¡~Åܬ°¹¡©Mªº³æÁä¡}C¢wC¡~¡A¥i¨Ï¯×½è§ó¥[í©w¡A¦p²B¤Æªo¡C


®ñ¤Æ§@¥Î¡]Oxidation¡^¡G¤£¹¡©M¯×ªÕ»Ä»P®ñªº¤Æ¾Ç§@¥Î¡A¨Ï±o¤£¹¡©MªºÂùÁä¡}C=C¡~Åܬ°»Ä©Î§Î¦¨¹L®ñ¤Æ²{¶H¡A¥i¨Ï¯×½è«~½è­°§C¡A²£¥Íªo¯Ó¨ý©Î¹L®ñ¤Æª«¡C¦³¨Ç«h²£¥Íà¬Åé¡]Ketone bodies¡^¡A¦p²£¥Í¡G¤þଡ]Acetoacetic acid¡BAcetone¡B£]-hydroxybutyric acid¡^
¨m¤Æ§@¥Î¡]Saponification¡^¡G¯×ªÕ»Ä»PÆP©Êª«½èªº¤Æ¾Ç§@¥Î¡A²£¥Í¨m¤Æ§@¥Î¡A±`¥Î©óªÎ¨m¤§¥[¤u¡C


»Ä±Ñ§@¥Î¡GÂùÁä¦ì¸mªººÒ®e©ö»P®ñ¶i¦æ®ñ¤Æ§@¥Î¡A°ª·Å­¹¤ÏÀ³§ó§Ö¡A¤Þµo¤@³s¦êªº¤À¸Ñ©Î»E¦X¤ÏÀ³¡A²£ª«¦³¤£¨}ªºÃC¦â©M®ð¨ý¡A³y¦¨ªo¯×®ñ¤Æ»Ä±Ñ¡A²£¥Í¹L®ñ¤Æª«¡A¨Ï±oªo¯×ªº«~½è­°§C¡C
¡@


²Ä¤G¸` ¯×½è¤ÀÃþ     [top]

1. ºÒ¼Æ©ÎºÒÃìªø«×¡G¯×ªÕ»Ä¤À¤lªºªø«×¤ÑµMªº¯×ªÕ»Ä¤À¤l©Ò§tªººÒ­ì¤l­Ó¼Æ³q±`¬°°¸¼Æ¡A¥HCnªí¥Ü¡AC¥NªíºÒ­ì¤l¡An¥NªíºÒ­ì¤lªº¼Æ¥Ø¡C¯×ªÕ»Ä¨ÌºÒ¼Æ¥i¤À¬°µuÃì¡]ºÒ¼Æ4-6­Ó¡^¡B¤¤Ãì¡]ºÒ¼Æ8-12­Ó¡^»PªøÃì¡]ºÒ¼Æ¤j©ó©Îµ¥©ó14­Ó¡^¯×ªÕ»Ä¤TÃþ¡CºÒÃì¶Vªø¡A«Ç·Å¤U¶V®e©ö¾®©T¦Ó§Î¦¨©TºA¡C

2. ÂùÁ伯¥Ø©Î¹¡©M«×¡G¯×½è¥i¤À¬°¤£¹¡©M¯×ªÕ»Ä¤Î¹¡©M¯×ªÕ»Ä¡A¯×ªÕ»ÄªººÒ­ì¤l¤§¶¡¦pªG¥þ³¡¥H³æÁä¡}C¢wC¡~µ²¦X¡A´NºÙ¬°¹¡©M¯×ªÕ»Ä¡]Saturated fatty acid, SFA¡^±`¨£ªº¦³µw¯×»Ä¡]Stearic Acid¡^¬°18­ÓºÒªº¹¡©M¯×ªÕ»Ä¡B´ÄÃq»Ä¡]16­ÓºÒªº¹¡©M¯×ªÕ»Ä¡^¡Bªo»Ä¡]16­ÓºÒªº¤£¹¡©M¯×ªÕ»Ä¡^µ¥¡C¦p¦³ÂùÁä¡}C=C¡~¡A´NºÙ¬°¤£¹¡©M¯×ªÕ»Ä¡]Unsaturated fatty acid, UFA¡^¡C¯×ªÕ»Ä¤§ÂùÁ伯¥Ø¥i¥H²Å¸¹Cn:xªí¥Ü¡An¬°ºÒ­ì¤l­Ó¼Æ¡Ax¬°ÂùÁä­Ó¼Æ¡C¤£¹¡©M¯×ªÕ»Ä¥i¥H¨ÌÂùÁä­Ó¼Æ¤À¬°³æ¤¸¤£¹¡©M¯×ªÕ»Ä¡]Monounsaturated fatty acid, MUFA¡^»P¦h¤¸¤£¹¡©M¯×ªÕ»Ä¡]Polyunsaturated fatty acid, PUFA¡^¨âÃþ¡C

³æ¤¸¤£¹¡©M¯×ªÕ»Ä§t¦³¤@­ÓÂùÁ䪺¤£¹¡©M¯×ªÕ»Ä¡A¦pªo»Ä¡A©óªá¥Íªo¡B¾ñÆVªo¤¤¡C¦h¤¸¤£¹¡©M¯×ªÕ»Ä§t¦³¨â­Ó©Î¥H¤WªºÂùÁ䪺¤£¹¡©M¯×ªÕ»Ä¡A¦p¨È³Âªo»Ä¡B¦¸¨È³Âªo»Ä¡A©ó´ÄÃqªo¡B½­µæªo¤Î³½ªo¤¤¡CÂùÁä·U¦hªí¥Ü¹¡©M«×¶V§C¡A©Î·U¤£¹¡©M¡C·íªo¯×§t¤£¹¡©M¯×ªÕ»Ä¶V¦h¡A«Ç·Å¤U§e²GÅ骬ºA¡A¦Ó§t¹¡©M¯×ªÕ»Ä·U¦h¡A«h©ö¬°©TÅ髬ºA¡CÂùÁä¼vÅT¯×ªÕ»Äªº¦w©w©Ê¡AÂùÁä¦ì¸mªººÒ®e©ö»P®ñ¶i¦æ®ñ¤Æ§@¥Î¡A°ª·Å­¹¤ÏÀ³§ó§Ö¡A¤Þµo¤@³s¦êªº¤À¸Ñ©Î»E¦X¤ÏÀ³¡A²£ª«¦³¤£¨}ªºÃC¦â©M®ð¨ý¡A³y¦¨ªo¯×®ñ¤Æ»Ä±Ñ¡A²£¥Í¹L®ñ¤Æª«¡A¨Ï±oªo¯×ªº«~½è­°§C¡C³q±`¤£¹¡©Mªo¯×ÂùÁä¶V¦h¡A¦w©w©Ê¶V®t¡C

¤£¹¡©Mªo¯×ªºÂùÁäÂǥѲB¤Æ§Þ³N¥i¥HÂà¤Æ¦¨³æÁä¡A¦]¦Ó´£ª@ªo¯×ªº¦w©w©Ê¡C²B¤Æ§Þ³N¤]¥Î¨Ó»s³y´Óª«©Ê¥¤ªo¡A²GºAªº´Óª«ªo¸g¹L²B¤Æ«á¹¡©M«×¤É°ª¡AÅܦ¨Ãþ¦ü¥¤ªoªº©TÅé¡A¼W¥[í©w©ÊÀ³§ó¾A¦X¯MµHªº¥Î³~¡C


3. ÂùÁ䪺´X¦ó«¬ºA¡G¤£¹¡©M¯×ªÕ»ÄÁÙ¥i¥H¨ÌÂùÁ䪺´X¦ó«¬ºA¤À¬°¶¶¦¡¡]Cis- form¡^»P¤Ï¦¡¡]Trans- form¡^¨â«¬¡CÂùÁ䪺ºÒ­ì¤l¤W©Ò³sµ²ªº²B­ì¤l¡A­Y¦bÂùÁä¦P¤@°¼«h¬°¶¶¦¡¡A­Y¦b¤£¦P°¼¡A«h¬°¤Ï¦¡¡C¤ÑµMªo¯×¤¤ªº¤£¹¡©M¯×ªÕ»Ä¤j¦h¬°¶¶¦¡«¬ºA¡A¥u¦³¤û¨Å»P²B¤Æªo¯×§t¦³¤Ö¶q¤Ï¦¡¯×ªÕ»Ä¡A¥[¤uªo¯×¸û©ö²£¥Í¤Ï¦¡¯×ªÕ»Ä¡A¤£§Q©ó®ø¤Æ§l¦¬¡C¦h¤¸¤£¹¡©M¯×ªÕ»Ä¨Ì¬Û¾FÂùÁ䪺¦ì¸m¥i¤À¬°¦@³m¯×ªÕ»Ä¡}Conjugated fatty acid¡~»P«D¦@³m¯×ªÕ»Ä¡}Non-conjugated fatty acid¡~¡C¦@³m¯×ªÕ»Ä¬O¬Û¾FÂùÁ䤧¶¡¥u¶¡¹j¤@­Ó³æÁä¡A«D¦@³m¯×ªÕ»Ä¬O¬Û¾FÂùÁ䤧¶¡¶¡¹j¨â­Ó³æÁä¡C¤ÑµMªº¤£¹¡©M¯×ªÕ»Ä¤j¦h¼Æ¬O«D¦@³m¯×ªÕ»Ä¡C¬Y¨Ç¦@³m¯×ªÕ»Ä¥i¯à¦³¯S®íªº¥Í²z®ÄÀ³¡C


4. ¥Í²z¥²»Ý©Ê¡G¥²»Ý¯×ªÕ»Ä¬O¤HÅ餣¯à¦X¦¨¡A¬O¤HÅé©Ò»Ý­n¡A©Î¬O¦X¦¨¶q¤£¨¬ªº¯×ªÕ»Ä¡A¥²¶·¥Ñ­¹ª«¤¤¨Ñµ¹¡A·íÄá¨ú¶q¤£¨¬®É«h²£¥Í¯Ê¥F¯gµ¥¯e¯f¡C¥²»Ý¯×ªÕ»Ä¥]¬An6¨t¦C¤§¨È³Âªo»Ä¡]C18:2¡^»Pn3¨t¦C¤§¦¸¨È³Âªo»Ä¡]C18:3¡^¡C«D¥²»Ý¯×ªÕ»Ä«h¬O¤HÅé¥i¥H¦Û¦æ¦X¦¨¡A¤£»Ý­n¨Ì¿à­¹ª«¨ÑÀ³ªº¯×ªÕ»Ä¡C¦p¡G¨È³Âªo»Ä¡B¦¸¨È³Âªo»Äµ¥¥²»Ý¯×ªÕ»Ä¡A¨ä¥\¯à¬°·L¦åºÞ©M²Ó­M½¤¤§­«­n¦¨¤À¡A¯à§Î¦¨Áx©T¾Jà­¡B¦å²MÁx©T¾J¤Î¨ä¥L²üº¸»X¤§¦X¦¨¡]¦p«e¦C¸¢¯À¡^¡A¦³§U©ó¦å²G¤§¾®©T¡C

5. ¯S®í¥\¯à¤§¯×½è¡G¦p¯×³J¥Õ¡]Lipoprotein¡^¬O¯×½è»P³J¥Õ½è¥H«D¦@»ùÁäµ²¦Xªº½Æ¦Xª«¡A©ó¦å¼ß¤¤­t³d¹B°e¯×½è¡C¥i¤À¬°VLDL¡]Very low density lipoprotein¡^¡BLDL¡]Low density lipoprotein¡^¡BHDL ¡]High density lipoprotein¡^¡CÁC¯×½è¡G§ZÁC¯×¡]Lecithin¡^¡CÁޯ׽è¡G¬°¯«¸gÓi°ò¾J¤§­«­nª«½è¡A¸£¥Ì¯×Ãþ¡]Cerebroside¡^¤ÎÁޯ׽è¦å¼ß½¤µ²ºc¤§¤@¡C©T¾JÃþ¡GÁx©T¾J¡A¥Ñ¥Ö½§¸g¥Ñ¤é¥ú·Ó®g¯à¦X¦¨ºû¥Í¯ÀD²üº¸»X¡CEPA¬°À¦¨à¸£³¡µo¨|©Ò»Ý¡ADHA¬°²üº¸»X¡]¦p«e¦C¸¢¯À¡^¦X¦¨¤§«eÁͪ«¡C

6. ±`¥Îªo¯×¤§¤ÀÃþ¡G«ö­ì®Æ¦Ó¤À¡G°Êª«©Ê¯×ªÕ¡G½Þªo¡AÂûªo¡B¥¤ªo¡A³½ªo ´Óª«©Ê¯×ªÕ¡G¦UºØ¨F©Ôªo¦p¶À¨§ªo¡A¥É¦Ìªo¡A¸ªªáªo¡Aªãªáªo¡Aªá¥Íªo¡A¾ñÆVªo¡A·¦¤lªo¡A´ÄÃqªo¡B³Âªo¡B¦ÌÁRªoµ¥ ¤@¯ë­ì«h¬O°Êª«©Êªo¯×Äݩ󹡩Mªo¯×¡A´Óª«ªo«hÄݩ󤣹¡©Mªo¯×¡C¹¡©Mªo¯×¦b±`·Å¤U¬O©TÅ骺§ÎºA¡A©Ò¥H±`¨£ªº°Êª«ªo¡A¨Ò¦p½Þªo¬O¥Õ¦â©TÅé¡A¥¤ªo¬O¶À¦â©TÅé¡A¦Ó¶À¨§ªo¡BªÛ³Âªo¡Bªá¥Íªoµ¥´Óª«ªo³£¬O²GÅé¡C¦ý¬O¦³¨Ò¥~ªº±¡§Î¡A³½ªoÁöµM¨ú¦Û°Êª«¡A«o¬O¤£¹¡©Mªo¯×¡A±`·Å¬°²GºA¡A¦Ó·¦¤lªo©M´ÄÃqªoÁöµM¨Ó¦Û´Óª«¡A«o¬O¹¡©Mªo¯×¡A±`·Å¬O©TºA¡C

ªo¯×¥[¤u¤¤ªº²B¤Æ§Þ³N¥i¥H§ïÅܪo¯×ªº¹¡©M«×¡A¯×ªÕ»ÄªºÂùÁä¦]¥[²B¦Ó¦¨¬°³æÁä¡AÂǦ¹´î¤ÖÂùÁ䪺¼Æ¥Ø¡A¨Ï¹¡©M«×¼W°ª¡A¦Ó´£ª@ªo¯×ªºÃ­©w©Ê¡C²M­»ªo¬°½Þªo¥[¤u¦Ó¦¨¡A«Ç·Å¤U¬°²GºA¡A§NÂëh·|¾®µ²¦¨©TºA¡C


²Ä¤T¸` ¯×½è¤§®ø¤Æ¡B§l¦¬»P¥NÁ     [top]

1. ®ø¤Æ

¤fµÄ¡G­¹ª«¤¤ªºªo¯×§Î¦¨¯×ªÕ²y¡A¯×¸Ñ»Ã¯À¶}©l¶i¦æ¤À¸Ñ§@¥Î¡C®ø¤Æ¤À¸Ñ¯×ªÕªº»Ã¯À¦bÀ¦¨à´Á¦³¦Þ¯×¸Ñ»Ã¯À¡]Lingual lipase¡^¡AÀHµÛ³è²Gªº¤Àªc»P­¹ª«¶i¨ì­G¤¤¡C

­G¡G±N¤T»Ä¥Ìªoà­¨âºÝªº¯×ªÕ»Ä¤ô¸Ñ¤ÀÂ÷¡A¦b­G¤¤¤À¸Ñ¯×ªÕ¡A­º¥ý§@¥Î©ó¨âºÝ¯×ªÕ»Äªº¤ô¸Ñ¡A¥Í¦¨¡uÂù»Ä¥Ìªoà­¡v¡C»P¯×ªÕ»Ä¡A¤j¬ù¦³30%ªº¤T»Ä¥Ìªo୥ͦ¨¦¹Ãþ²£ª«¡C¦¨¤H¥D­n¬O§Q¥Î¯ØÅ¦¤Àªcªº¯×¸Ñ»Ã¯À¡A°t¦XÁx¥Ä´£¨ÑÁxÆQÀ°§U¡A±N¯×ªÕ¤À¸Ñ¥H¨Ñ§l¦¬¡C

¯×ªÕ¤£·»©ó¤ô¡A»Ý­nÂǧUÁxÆQ»P§ZÁC¯×ªº¨Å¤Æ§@¥Î§Î¦¨¯×ªÕ²y¡A§¡¤Ã¤À´²¦b¤ô¬ÛÀô¹Ò¤¤¡A¨Ã¥B¼W¥[»Ã¯À§@¥Îªºªí­±¿n¡A¥H§Q¯×¸Ñ»Ã¯À¶i¦æªo¯×ªº®ø¤Æ¤À¸Ñ¡C®ø¤Æ¬O¤@ºØ¤ô¸Ñ¤ÏÀ³¡A¯×¸Ñ»Ã¯À§â¤ô¤À¤l¥[¨ìà­Áä¤W¡A¦Ó¨Ï¯×ªÕ»Ä¤À¸ÑÄÀ©ñ¥X¨Ó¡C

§l¦¬¡G¤T»Ä¥Ìªoà­ªº®ø¤Æ²£ª«¦³³æ»Ä¥Ìªoà­¡B¥Ìªo»PµuÃì¡B¤¤Ãì¡BªøÃì¯×ªÕ»Ä¡C²£ª«¤¤¤£·»©ó¤ôªºªøÃì¯×ªÕ»Ä»PÁx©T¾Jµ¥»P³æ»Ä¥Ìªoà­¡BÁC¯×½è¡BÁxÆQ§@¥Î§Î¦¨·L¯×²É¡A¥HÂX´²ªº¤è¦¡¶i¤J¤p¸z²Ó­M¡C

¤p¸z¡G¨xŦ¦X¦¨ÁxÆQ¡A¸g¥ÑÁx¥ÄÄâ±a¨ì¤p¸z¡AÁxÆQªº¨Å¤Æ§@¥Î¨Ï¯×ªÕ²y§Î¦¨¸û¤pªº¯×ªÕ²É¡A¥H§Q»Ã¯Àªº§@¥Î¡C¤p¸z²Ó­M¤º¶i¦æ¤@¨t¦Cªº²Õ¦X§@¥Î¡A§â§l¦¬ªº¯×½è©M¦hºØ³J¥Õ½è¤@¦P²Õ¦X¦¨¨ÅÁS·L²É(Chylomicron)¡A¸g²O¤Ú¨t²Î¹B°e¦Ü¤jÅé´`Àô¡A¿é°e¦Ü©PÃä²Õ´»P¨xŦ§Q¥Î¡A¥H´£¨Ñ¯à¶q¡A¦X¦¨¿E¯À¡A©ÎÀx¦s¦b¯×ªÕ²Õ´¡C§l¦¬§@¥Î¤p¸z²Ó­M¡GµuÃì»P¤¤Ãì¯×ªÕ»Ä¡A¥H¤Î¥Ìªoª½±µ³q¹L¤p¸z²Ó­M½¤¡A¶i¤J·L¦åºÞ¡A¸g¥Ñ¨xªùÀR¯ß¹B°e¨ì¨xŦ¡C

2. §l¦¬

¯Ø²G¤¤ªº¯×¸Ñ»Ã¯À±N¤T»Ä¥Ìªoà­¨âºÝªº¯×ªÕ»Ä§¹¥þ¤ô¸Ñ¡A®ø¤Æ²£ª«¬O¡u³æ»Ä¥Ìªoà­¡v¡B¥Ìªo¡BµuÃì¡B¤¤Ãì»PªøÃì¯×ªÕ»Ä¡C ªøÃì¯×ªÕ»Ä¡B³æ»Ä¥Ìªoà­¡BÁx©T¾J¡BÁC¯×½è»PÁxÆQ§@¥Î§Î¦¨·L¯×²É¡C·L¯×²É¥HÂX´²§@¥Î³q¹L¤p¸z²Ó­M½¤¡A±Nªo¯×®ø¤Æ²£ª«°e¤J²Ó­M¡C¦b²Ó­M¤º¡AªøÃì¯×ªÕ»Ä»P³æ»Ä¥Ìªoà­µ²¦X¡A¥Í¦¨¤T»Ä¥Ìªoà­¡CªøÃì¯×ªÕ»Ä»P»Ý­n¤@ºØ»PAcyl coA§Î¦¨à­¤ÆªºÓi°ò»Ä¡]Carnitine¡^°e¤J²Ó­M¤º¤§²É½uÅé¶i¦æ£]®ñ¤Æ¤À¸Ñ¡C¤T»Ä¥Ìªoà­¡BÁC¯×½è¡BÁx©T¾Jµ¥»P³J¥Õ½è¤@¦P²Õ¦X¦¨¨ÅÁS·L²É¡A¶i¤J²O¤ÚºÞ¹B°e¡A©óÀV³¡ªþªñ°e¤J¦å²G´`Àô¡C

ªo¯×®ø¤Æ«á¡A¤ô·»©Ê²£ª«¥Ñ·L¦åºÞ¹B°e¡Cªo·»©Ê²£ª«¥Ñ¨ÅÁSºÞ»PªL¤Ú¨t²Î¹B°e¡C

3. ¹B°e

ªo¯×¤£¯à·»¸Ñ¦b¤ô·»²G¤¤¡A¦]¦¹¦b¦å¼ß¤¤±Ä¥Î¯S§Oªº¹B°e§Î¦¡¡AºÙ¬°¯×³J¥Õ¡]Lipoproteins¡^¡A³o¬O¥Ñ¯×½è»P³J¥Õ½è©Òºc¦¨ªº¡A§t¯×½è¶V¦h«h¤ñ­«¶V»´¡A¯×½è¥]§t¤T»Ä¥Ìªoà­¡AÁx©T¾J©MÁC¯×½è¡C

4. ¥NÁ§Q¥Î¡G

¡]1¡^²Õ´¥NÁ§Q¥Î¡G¨Ó¦Û­¹ª«ªº¯×ªÕ§l¦¬«á§Î¦¨¨ÅíÝ·L²É¡A¦b¦åºÞ¤¤¹B°e¦Ü¦U²Õ´¡C¨xŦ¥Í¦¨VLDL¡A±N¯×ªÕ´£¨Ñµ¹¨ä¥L²Õ´¡A¨xŦ·s¥ÍªºHDL¨ã¦³¦¬¶°Áx©T¾Jªº¯à¤O¡C¯×³J¥Õ¦b¦åºÞ¤¤´`Àô¹Lµ{¡A¨ä¯×½è³vº¥¥NÁ¦ÓÅܤơA¦åºÞ¤º¾À¤W§t¦³»Ã¯À¯×³J¥Õ¯×¸Ñ»Ã¯À¡]Lipoprotein lipase¡^¡A­t³d¤ô¸Ñ¯×³J¥Õ¤¤ªº¥Ìªoà­¥H¨Ñ²Ó­M§Q¥Î¡C¯×ªÕ²Ó­M§t¦³¯×³J¥Õ¯×¸Ñ»Ã¯À¡A¥i¤À¸ÑÀx¦sªo¯×¡AÄÀ¥X¯×ªÕ»Ä¨Ñ¨ä¥L²Õ´§Q¥Î¡C

¡]2¡^²Ó­M¤ºªº§Q¥Î¡G¯×ªÕ»Ä¥i¥H®ñ¤Æ¥Í¦¨ATP¡A¨ÑÀ³¥Í©R©Ò»Ýªº¯à¶q¡A¯×ªÕ²Ó­M©Î¨xŦ¥i¥H±N¯×ªÕ»ÄÂন¤T»Ä¥Ìªoà­Àx¦s¡A¯×ªÕ»Ä¥i¥H¥Ñ³æÁÞ»P®ò°ò»Ä¥NÁ¦X¦¨¡C

5. ±Æªn¡G

¡]1¡^®ø¤Æ§l¦¬¤£¨}®É¡AÁT«K¤¤§t¦³¤j¶q¯×ªÕ¡A¦¹¯gª¬ºÙ¬°¯×µg¡A

¡]2¡^Áx©T¾J¦b¨xŦ¦X¦¨Áx»Ä©ÎÁxÆQ¡AÀHµÛÁx¥Ä¬y¤J¤p¸z¡A¦pªG»P¿¯­¹ÅÖºû©Î¨ä¥Lª«½èµ²¦X¡A¤p¸zµLªk§l¦¬¡A¹F¨ì­°§C¦åÁx©T¾Jªº®ÄÀ³¡A§¿²G¤¤³q±`¨S¦³¯×ªÕªº±Æ¥X¡C

6.¤HÅ骺¯×ªÕ²Õ´¡G

¤HÅ餤¶J¦s¦³¨âÃþ¯×ªÕ²Õ´

¡]1¡^¥Õ¦â¯×ªÕ²Õ´¡G¯×ªÕ²Ó­M¤¤¤ß¬°³æ­Ó¯×ªÕ²y¡A²Ó­M®Ö©M²Ó­M½è³£³QÀ£À½¨ìÃä½t¡A¥D­nªº¥\¯à¬OÀx¦s¯×ªÕ¡C

¡]2¡^´Ä¦â¯×ªÕ²Õ´¡G²Õ´§t¦³¤j¶q·L¦åºÞ¡AÃC¦â¸û¬°²`·t¡A¨ä¯×ªÕ²Ó­M§t¦³¼Æ­Ó¤j¤p¤£¤@ªº¯×ªÕ²y¡A²É½uÅ鼯¥Ø¯S§O¦h¡A¥D­nªº¥\¯à¬O²£¼ö¥Hºû«ùÅé·Å¡A¹ïÅé­«¤]¦³¼vÅT¡A¯Ê¤Ö´Ä¦â¯×ªÕ²Õ´ªº°Êª«¦³ªÎ­Dªº²{¶H¡C

²Ä¥|¸` ¯×½èªº»Ý­n¶q     [top]

¤@¡Bªo¯×¤§Äá¨ú­ì«h¡G

1. ¨C¤éªo¯×Äá¨ú¶q¤£¶W¹LÁ`¼ö¶qªº30%¡C¦pªG¤@¤Ñ»Ý­n¼ö¶q1800¤j¥d¡A«hªo¯×¤§Äá¨ú¶q¤£À³¶W¹L60¤½§J¡C

2. ¹¡©M¯×ªÕªºÄá¨ú¶q¨C¤Ñ¤£¶W¹LÁ`¼ö¶qªº10%¡C

3. ¥²»Ý¯×ªÕ»Ä¤§»Ý­n¶q¤£§C©óÁ`¼ö¶qªº2-3¢H¡C¦p¡Gn6¯×ªÕ»Ä¡A¬°¤Fº¡¨¬¨­Åé©Ò»Ýªº¥²»Ý¯×ªÕ»Ä¡A¨È³Âªo»ÄC18:2À³¦ûÁ`¼ö¶qªº2%¡A°²³]¨C¤Ñ¼ö¶qÄá¨ú1800¤j¥d¡A«hÀ³§t¦³36¤j¥d¡A¬Û·í©ó4¤½§J¡A§Y2¤p°Í¡]¯ù°Í¡^¨F©Ôªo¡Cn3¯×ªÕ»Ä¡G¦¸¨È³Âªo»ÄC18:3¤]¬O¥²»Ý¯×ªÕ»Ä¡A¨C¤Ñ¤j¬ù»Ý­n3¤½§J¡A¦ý¬O¤@¯ëªo¯×¤¤ªº§t¶q¨Ã¤£°ª¡A°£¤F¬Y¨Ç´Óª«ªo¥i¥H¨ÑÀ³¤§¥~¡A¨C¶g¦Ü¤ÖÄá¨ú¨â¦¸°ª¯×®ü³½¡A¨Ò¦pÂD³½©ÎÂC³½¡C¦h¤¸¤£¹¡©M¯×ªÕ»Ä¬ù¦û¼ö¶q3-7%¡C

4. Áx©T¾J¨C¤Ñ¤£¶W¹L300²@§J¡C

¤G¡B¬ü°ê2000¦~¤ßŦ¾Ç·|±Ä¥Î°·±dªº¶¼­¹«¬ºA¡G

1. Äá¨ú¦h¼Ëªº½­µæ¡B¤ôªG¡A¨C¤Ñ 5 ¥÷¥H¤W

2. Äá¨ú¦h¼Ëªº¤­âBÃþ»P¥þâBÃþ­¹«~¡A¨C¤Ñ 6 ¥÷¥H¤W

3. ±Ä¥Îªo¯×¶q§C¤§¨Å«~¡B³½¡B¨§Ãþ¡BÂû¦×¡B½G¦×µ¥

4. ªo¯×Ãþ¿ï¥Î¹¡©Mªo¯×§Cªº²£«~¡A¨Ò¦p¡G²GºAªo¡Bªãªáªo¡B¾ñÆVªo

5. ¼ö¶qÄá¨ú°t¦X¨C¤Ñªº¼ö¶q®ø¯Ó¡AÁ×§K¼ö¶q°ª¦ýÀç¾i»ù­È§Cªº­¹ª«

6. ºû«ù°·±d©Ò»Ýªº¤é±`¬¡°Ê¡AÄá¨ú¥­¿Å¶¼­¹¡A¨C¤ÑÀ³¨B¦æ©Î¨ä¥L¬¡°Ê30¤ÀÄÁ

7. Á×§K¼ö¶q°ª©ÎÀç¾i»ù­È§Cªº­¹ª«¡A¨Ò¦p§t¿}ªº¶¼®Æ»P¿}ªG²¢ÂI

8. Á×§K¹¡©M¯×ªÕ»PÁx©T¾J©Î¤Ï¦¡¯×ªÕ»Ä°ªªº­¹ª«¡A¨Ò¦p¡G¥þ¯×¥¤¡BªÎ¦×¡B§t²B¤Æªo¤§¯MµH©Îªo¬µ­¹«~¡B¼ö±aªo¯×¡B³J¶Àµ¥

9. ­¹ÆQÄá¨ú¶q¨C¤Ñ¤£¶W¹L6¤½§J¡]¶u2400²@§J¡^¬°©y

10. ¨C¤ÑÄá¨ú°sºë­­¶q¡G¤k©Ê15²@¤É¡A¨k©Ê30²@¤É¡F15²@¤É°sºë¬Û·í©ó¤@¤pªM¯P°s¡A©Î¤@°sªM¬õ°s¡A©Î¤@Åø°à°s¡C


·í¤HÅé¹ï¯à¶qªº»Ý¨D«Ü¤j®É¡A§tªo¯×¦hªº¶¼­¹´N«Ü­«­n¡Q¨Ò¦pÀ¦¨àªº¦¨ªø§Ö³t¡A¤@¦~¤§¤ºÅé­«¼W¥[¤T­¿¡A¦ý¬O­G®e¶q«Ü¤p¡A©Ò¥H¥À¨Å©MÀ¦¨à¥¤¯»¤¤ªo¯×¨ÑÀ³ªº¼ö¶q°ª¹F55%¡A°ª©ó¦¨¤Hªº30%«ØÄ³¶q¡QÀ¦¨à¤£¥i¶¼¥Î²æ¯×©Î§C¯×¤û¥¤¡A¤]¤£¾A¦X¶¼¥Î·Ò¨Å¡A³o¨Ç³£·|³y¦¨Àç¾i¯Ê¥Fªº°ÝÃD¡C

ºû«ù°·±d¦X©yªºÅé­«¡G

1. ¼ö¶qÄá¨ú°t¦X¨C¤Ñªº¼ö¶q®ø¯Ó¡AÁ×§K¼ö¶q°ª¦ýÀç¾i»ù­È§Cªº­¹ª«

2. ºû«ù°·±d©Ò»Ýªº¤é±`¬¡°Ê¡A¥H¥­¿Å¯à¶qªºÄá¨ú

3. ´î­«®É¼ö¶q®ø¯Ó¤@©w­n¶W¹LÄá¨ú¶q


±±¨î¦å¯×
»PÁx©T¾J¡G

1. ¹ï¹¡©M¯×ªÕ»Ä»PÁx©T¾J¡A©Î¤Ï¦¡¯×ªÕ»Ä°ªªº­¹ª«À³¸`¨î­¹¥Î

2. ªo¯×¨Ó·½ºÉ¶q§Q¥Î¤­âBÃþ¡B½­µæ¡B³½¡B¨§¡B°íªGÃþ´£¨Ñ¤§¤£¹¡©Mªo¯×
ºû«ù°·±d¦åÀ£¡G

3. ­¹ÆQÄá¨ú¶q¨C¤Ñ¤£¶W¹L6¤½§J¬°©y

4. ¸`¨î°sºëÄá¨ú


¤T¡B°ê¤H¤§ªo¯×Äá¨úª¬ªp


¨Ì¾Ú¥xÆW¾ú¦~°ê¥ÁÀç¾i½Õ¬dµ²ªG¡A¦¨¤H¨k¤l¨C¤H¨C¤é¤§¥­§¡Äá¨ú¶q½d³ò¬O81-90¤½§J¡A¦ûÁ`¼ö¶qªº¤ñ¨Ò¬°31.7%-36%¡C¦Û¥Á°ê75¦~¥H¨Ó°ê¤Hªo¯×Äá¨ú¶q¶W¹L½Ã¥Í¸p«ØÄ³¤§30%¡C¦Ó³Ìªñªº°ê¥ÁÀç¾i°·±dª¬ªpÅܾE½Õ¬dµ²ªG¡A19-64·³¨k©Ê¨C¤H¥­§¡ªº¯×ªÕÄá¨ú¶q¬ù¬°¨C¤Ñ79.5¤½§J¡A¦ûÁ`¼ö¶q¤§33.5%¡F19-64·³¤k©Ê¨C¤H¥­§¡ªº¯×ªÕÄá¨ú¶q¬ù¬°¨C¤Ñ61.1¤½§J¡A¦ûÁ`¼ö¶q¤§34.4%¡C

°ê¤H¶¼­¹¤§¯×ªÕ»Ä¤À°t¤ñ¨Ò¬°¥H¹¡©M¡}S¡~¡G³æ¤£¹¡©M(M)¡G¦h¤£¹¡©M(P) ªí¥Ü¡A¨k©Ê¤j¬ù¬O0.85/1.17/1¡A¤k©Ê¬O0.95/1.15/1¡FP/S¤ñ¨Ò±µªñ©ó1¡A¤ñ¼Ú¬ü°ê®a¬°Àu¡C¨C¤H¨C¤éªºÁx©T¾JÄá¨ú¶q¥­§¡¬°¨k©Ê344²@§J¡A¤k©Ê264²@§J¡C¨ÑÀ³ªo¯×ªº¥D­n­¹ª«¨Ó·½¡A²Ä¤@¦ì¬O®a¯bÃþ¤Î¨ä»s«~¡A¯S§O¬O½Þ¦×¤Î¨ä¥[¤u«~¡A¨ä¦¸¬Oªo¯×Ãþ¡A¥H´Óª«ªoÃþ¬°¥D¡CÁx©T¾Jªº¥D­n­¹ª«¨Ó·½¬O·sÂA³JÃþ¡A¦×¤Î¦×¥[¤u«~¡C

¥|¡B±±¨î¶¼­¹¯×ªÕ¶qªº¤èªk

¥Ñ©ó¤ß¦åºÞ¯e¯fªº¦MÀI¦]¤l¤¤¡A¿}§¿¯f¡A°ª¦åÀ£¡A°ª¦å¯×©MªÎ­D¬O»P¶¼­¹ª½±µ¦³Ãöªº¡A¥i¥H¹B¥ÎÀç¾iª¾ÃÑ¥[¥H±±¨î©Î½Õ¾ã¶¼­¹¡CÁöµM¡A¦åºÞ¤¤³£©Î¦h©Î¤Ö¦³¯×ªÕªº°ï¿n¡A¦ý¬O¡A¨}¦nªº¥Í¬¡¤Î¶¼­¹²ßºD¦³§U©ó´î½w°ï¿nªº³t«×¡C

¤­¡B­¹ª«¿ï¥Î­ì«h¡G

¿ï¥Î¯×ªÕ§t¶q§CªÌ¡A¦p¡G¥ÍÂAÃþ¤­½\®Ú²ôÃþ¡A²æ¯×¥¤¡B§C¯×¥¤¡B§C¯×Àu¹T¨Å¡B§C¯×°_¥q¨Å¹Tµ¥¥¤Ãþ¡B¨Å»s«~¡CÂû¦×¡B¥þ½Gªº½Þ¡B¤û¦×¨Ì¶·­n¿ï¥Î¡A½­µæ¤ôªGÃþ¬Ò¥iÀH·N¿ï¥Î¡A¨C¶g¤T¦¸¥H¤W¡An-3¯×ªÕ»Ä³½¨©®üÂA¡C¤Ö¥Î°ª¯×ªÕªº²£«~¡A¦p¡Gªo¶º¡B°ªªoÄÑ¥]¥þ¯×¥¤¡B¦B²N²O¡B°_¥q¨Å¹T¡B¤T¼h¦×¡B¤­ªá¦×¡B­»¸zþ¦×µ¥¡C

¤»¡B§C¯×²i½Õ­n»â¡G

1. ¥h°£¦×Ãþ¥i¨£ªº¯×ªÕ¡AÂûÀn¥h¥Ö

2. ¬õ¿N¦×Ãþ©Î¿LµN¦×´ö«á¡A¥i¥ý¦s©ñ¦b¦B½c¤º¡A¹j¤é¥h±¼¯B°_¾®µ²ªºªo«á¦A¥[¼ö­¹¥Î

3. ¥Î²M»]¡B¤t¿S¡B¬õ¿N¡B·Lªi¡B¯M¯N¥N´Àªoª£©Îªo¬µªº²i½Õ

4. ±Ä¥Î´î¤Ö¥Îªo¶qª£µæ¡A±Ä¥Î­»®Æ¡B¾L¡B½µ¡B»[µ¥¼W¥[­·¨ý¡A¨Ï¥Î¶q°Í±±¨î²K¥[ªºªo¶q¡Aµ½¥ÎÁç¨ã´î¤Ö¥Îªo¶q¡C

²Ä¤­¸` ¯×½è»P¤ß¦åºÞ¯e¯f¯×½è¤§¯Ê¥F¯g     [top]

¤ß¦åºÞ¯e¯f¬O¤ßŦ¯f»P¦åºÞ¯e¯fªºÁ`ºÙ¡C«aª¬°Ê¯ß¬O¨ÑÀ³¤ßŦ®ñ®ð»P¾i¤Àªº¦åºÞ¡A·í¨ÑÀ³¤ßŦªº¦å²G´î¤Ö¦Ó¹ï¤ßŦ³y¦¨¶Ë®`§Î¦¨¤ßŦ«aª¬°Ê¯ß¯e¯f(Coronary heart disease)¡A°Ê¯ßµ°ª¬µw¤Æ(Atherosclerosis)»P°ª¦åÀ£¬O±`¨£ªº¯e¯f¡Cµ°ª¬µw¤Æ¬O«ü°Ê¯ßºÞ¾À¤W¥Í¦¨¸~¶ô¡A¥Ñ¥­·Æ¦Ù²Ó­M¡BÅÖºû³J¥Õ½è¡B¯×ªÕ¡B²Ó­M´Ý´íºc¦¨¡A¨Ã¦³µ{«×¤£¤@ªº¥X¦å¡BÃa¦º¡B¶t¤Æªº²{¶H¡Aµ°ª¬µw¶ô¥~³ò±`ªþ¦³¦å®ê¡C

¦åºÞ¾À¦]¦¹µw¤Æ²ÊÁW¤£¥­¡BºÞ®|Åܤp¡A¦å¬yªý¤O¼W¤j¡B¦å¬y¶q´î¤Ö¡B²Õ´Àò®ñ»P¾i¤À¨ÑÀ³´î¤Ö¡C¦åºÞ¾À©Ó¨üÀ£¤O¤j¡A®e©ö¨ü¶Ë¡A¦Ó©ö¥Í¦¨¦å®ê¡A¨Ïªý¶ëªº±¡ªp§ó¬°´c¤Æ¡C³Ì«á²£¥Í½ÆÂø¦Ó¤£¥i°fªº¦åºÞ¾Àµ°ª¬¶ô¡C

°Ê¯ßµw¤Æ°_¦]©ó¦å¤¤LDL®ñ¤Æ©Ò¤Þ°_ªº¦åºÞ¾À¯fÅÜ©Mµoª¢¤ÏÀ³¡A¯f¯g¦³¶¥¬q©ÊªºÅܤơC­º¥ý¡A¦å¤¤¹L¶qªºLDL»E¶°¦b°Ê¯ß¤º¾À¤W¨Ã¥Bµo¥Í®ñ¤Æ¡A¨ë¿E¤º¥Ö²Ó­M¤ÀªcÂH©Ê¤À¤l¡A§l¤ÞT²Ó­M©M³æ®Ö²y²Ó­MÂHªg¨Ã«I¤J¦åºÞ¤º½¤¡C¦b¦åºÞ¤º½¤¡A³æ®Ö²y¬¡¤Æ¦¨¬°¥¨¾½²Ó­M¡A²£¥Í³\¦hµoª¢ª«½è¡A¨Ã¥B§]¾½¤j¶qªº®ñ¤ÆLDL¡A§Î¦¨¯×ªÕ°ï¿nªºªw²Ó­M¡]foam cells¡^»P¯×ªÕ¶ô¡A³o¬Oµ°¸~ªºªì´Á¡A¦¹¶¥¬q¬°¥i°f©Ê¡A¦pªG§´µ½¹w¨¾¥i¥H°fÂà¶Ë®`©ÊªºÅܤơC

¸~¶ô¥H¯×ªÕ¬°¤¤¤ß³vº¥¼W¤j¡A³Q¶gÃ䪺¦Ù¦×²Ó­M¥]³ò¡A¦Ù¦×²Ó­M§Î¦¨ÅÖºûª¬µw´ß¡A¹jÂ÷¸~¶ô»P¦å¬y¡Cªw²Ó­M¤Àªc¦hºØµoª¢ª«½è¡A¯}Ãa©P³òªº¦Ù¦×²Ó­M»PÅÖºûª¬µw´ß¡A¾É­P¸~¶ô¯}µõ¦ÓµLªk­×´_¡A·l¶ËªººÞ¾À²Õ´ÄÀ¥Xªº¦¨¤À·|«P¶i¦å¤pªO¾®¶°¡A§Î¦¨¾®¦å¶ô©Î¦å®ê¡A¦å®ê©Î¦å¶ô¹L¤j´N·|ªý¶ë¦å¬y¡Aµo¥Í©ó¸£¦åºÞ«h¬O¤¤­·¡Fµo¥Í©ó¤ßŦ¦åºÞ«h¬O¤ß¦Ù±ð¶ëªº­ì¦]¤§¤@¡A¤ß¦Ù¦]¯Ê®ñ¦ÓÃa¦º¡C

¤@¡B¤ß¦åºÞ¯e¯fªº¦MÀI¦]¤l¡G

¥D­n¦MÀI¦]¤l

1. ¿ò¶Ç(®a±Ú¯f¾ú) ¡G¦­µo©ÊCAD¡]½T©w¬°¤ß¦Ù±ð¶ë¡B¤÷¿Ë©Î¨k©Ê¤@µ¥¿Ë¦b55·³¥H«eÖ`¦º¡B¥À¿Ë©Î¤k©Ê¤@µ¥¿Ë¦b65·³¥H«eÖ`¦º¡^¡C

2. ©Ê§O¡G¨k©Êªº¦MÀI°ª©ó¤k©Ê

3. ¦~ÄÖ¡G¨k©Ê¡Ù45¡A¤k©Ê¡Ù55¡A©Î¹L¦­°±¸g¦ÓµL¤k©Ê²üº¸»XªvÀø

¥i¹w¨¾¤§¦MÀI¦]¤l

4. ¸g±`©Ê©â·Ï

5. °ª¦åÀ£¡G¦åÀ£¡Ù140/90 mmHg©ÎªA¥Î°ª¦åÀ£ÃĪ«

6. ¦å¯×²§±`¡G¦å¯×¤§¤À¯Å¼Ð·Ç¦p¤U¡AÁ`Áx©T¾J²z·Q­È< 200¡A°¾°ª200~239²§±`°¾°ª¡Ù240¤T»Ä¥Ìªoà­²z·Q­È< 150°¾°ª150~199²§±`°¾°ª200~499ÄY­«¹L°ª¡Ù500¡FLDL Áx©T¾J²z·Q­È< 100²¤°ª100~129°¾°ª130~159²§±`°¾°ª160~189ÄY­«¹L°ª¡Ù190 HDL Áx©T¾J°¾§C< 40²z·Q¡Ù60

¤G¡B­°§C¤ß¦åºÞ¯e¯fªºµ¦²¤¡G

1. ¶¼­¹½Õ¾ã¡G¥H­°§CLDL»P¤É°ªHDL¬°¥Ø¼Ð¡GÁ×§K¼ö¶q¹L³Ñ¡A¸`¨îªo¯×ªºÁ`Äá¨ú¶q¡A¿ï¥Î³æ¤¸¤£¹¡©Mªo¯×¡A±±¨î¹¡©M¯×ªÕ¡Ø7%¼ö¶q¡A¦h¤¸¤£¹¡©M¯×ªÕ»Ä¥i­°§CLDL¡A¦ýµLªk¼W¥[HDL¡CÁx©T¾J¨C¤Ñ¡Ø200 mg¡AÄá¨ú¨¬¶q¤ô·»©Ê¿¯­¹ÅÖºû¡A¿ï¥Î½­µæ¡B¤ôªG¡B¨§Ãþ¡B¤­½\Ãþ¡A§Q¥Î½­µæ¡B¤ôªG¡B¨§Ãþ´£¨Ñ§Ü®ñ¤Æ¦¨¤À»PB¸sºû¥Í¯À¡C

2. ¥Í¬¡«¬ºA¡Gºû«ù²z·QÅé­«¡AÁ×§KÅé­«¤W¤É¡A§ÙµÒ¡A¨C¤ÑÀ³¸Ó¦³30¤ÀÄÁªº¬¡°Ê¡AÁ×§KÀRºA¥Í¬¡¡C

3. ±±¨î¦åÁx©T¾J¡G20·³¥H¤W¦¨¤HÀ³¨C5 ¦~´ú¶q¦åÁx©T¾J»P¦å¯×ÃЫ¬¡A¥H¤F¸Ñ¦å¯×ªº¾ãÅ骬ªp¡A¥]¬AÁx©T¾J¡B¤T»Ä¥Ìªoà­¡BLDL¡BHDLµ¥¡C

4. ¼W¥[¦³¯q¤ßŦ¦åºÞ«O°·ªº¶¼­¹¦¨¤À¡G§Ü®ñ¤Æ¦¨¤À¡Gºû¥Í¯ÀE»P¦UºØ´Óª«¥\®Ä¦¨¤À¡A§í¨î¦å¤¤¯×½èªº®ñ¤Æ¡BB¸sºû¥Í¯À¡G¸­»Ä¡BB6¡BB12¥R¨¬¡A­°§C¦å¤¤¦P¥b¥úÓi»Ä¿@«×¡A­°§C¦åºÞ·l¶Ë¡Bn3¯×ªÕ»Ä¡G´î¤Ö¦å®ê¥Í¦¨¡A¥i¯à§í¨îµoª¢¤ÏÀ³¡B¿¯­¹ÅÖºû¡G¼W¥[ÁxÆQ±Æªn¡A­°§C¦åÁx©T¾J¡B¶À¨§³J¥Õ½è¡G¨C¤ÑÄá¨ú25¤½§J¦³§U©ó­°§C¦åÁx©T¾J¡C

ÀHµÛ°ê¤H¤ß¦åºÞ¯e¯fµ¥¤å©ú¯f¿©±w²vªº¤W¤É¡A¤ßŦ¯e¯f¦MÀI©Êªºµû¦ô¥u¯à¥Ñ¤@¨Ç¦MÀI¦]¤l±À´ú¨äµo¥Í²v¡C»P¤ßŦ¦åºÞ¯e¯f¦³¥¿¬ÛÃö©Êªº¦MÀI¦]¤l¬O¡G¿ò¶Ç¡B©Ê§O¡B¦~ÄÖ¡B©â·Ï¡B¿}§¿¯f¡B°ª¦åÀ£¡BªÎ­D¡Bºò±iÀ£¤O¡B¤Î¯Ê¥F¹B°Ê¡C

¤T¡Bªo¯×»PÀù¯g

¨Ì¾Ú¬y¦æ¯f¾ÇÆ[¹î¡G°ê®a¤§¶¡ªº¤ñ¸û¡Aªo¯×Äá¨ú°ªªº°ê®a¡A¨ÅÀù»P¤j¸zÀùªº¦º¤`²v¸û°ª¡C

®Ú¾Ú¦è¤è°ê®aªº¬ã¨s¡A»PÀù¯g¦³Ãöªº¶¼­¹¦]¯À¥i¯à¬O¼ö¶q¹L³Ñ¡A¦Ó«D³æ¯Âªºªo¯×Äá¨ú¶q¡C¬ü°êÀù¯gÂå¾Ç·|¡}American Cancer Society¡~«ØÄ³ªº¨¾Àù¶¼­¹»P¥Í¬¡­ì«h ¡GÄá¨ú°·±d¦h¼Ëªº­¹ª«¡Aµ½¥Î´Óª«©Ê­¹«~¡G¨C¤ÑÄá¨ú¤­¥÷½­µæ©M¤ôªG¡BÀu¥ý¿ï¥Î¥þâBÃþ­¹ª«¡Bªo¯×°ª©Î¥[¤uªº¬õ¦×»s«~©y¸`¨îÄá¨ú¡B¤é±`¶¼­¹¥Hºû«ù°·±dÅé­«¬°¥Ø¼Ð¡B°ö¾i¬¡¤O¦n°Êªº¥Í¬¡«¬ºA¡B¦¨¤H¡G¨C¤ÑÀ³¦³¤¤«×¬¡°Ê30¤ÀÄÁ¡A¨C¶g¦Ü¤Ö¹ê¦æ¤­¤Ñ¡B¨àµ£»P«C¤Ö¦~¡G¨C¤ÑÀ³¦³¤¤«×¦Ü¼@¯Pªº¬¡°Ê60¤ÀÄÁ¡A¨C¶g¦Ü¤Ö¹ê¦æ¤­¤Ñ¡C

¤@¥Íºû«ù°·±dªºÅé­«±Ä¦æ°ÊºAªº¥Í¬¡¨Ó¥­¿Å¼ö¶qªºÄá¨ú¡B¹L­«©ÎªÎ­DªÌ©y¶}©l°õ¦æ´î­«­p¹º¡C¶¼°s°È¥²¸`¨î¥Î¶q¡A¤k©Ê¨C¤Ñ¤@ªM¡A¨k©Ê¨C¤Ñ¨âªM¬°­­¡C¶¼°s»P¤k©Ê¨ÅÀù¦³±K¤ÁªºÃöÁp¡C

¥|¡B¯×ªÕ¤£¨¬¤§¯Ê¥F¯g¡G

¶¼­¹¤¤¯×ªÕÄá¨ú¤£¨¬®É¡A³y¦¨Åé¯×ªÕ¤£¨¬¡A¨Ï±o¨àµ£¥Íªø¿ðº¢¡A¤k©Ê«h·|°±¸g»P¤£¥¥ªº²{¶H¡C


¤pÀɮסGOmega-3¯×ªÕ»Ä     [top]

Omega-3¯×ªÕ»Ä¡G³½ªo¤¤§t¦³«Ü¦h¤§Omega-3¯×ªÕ»Ä¡A¥]¬AEPA¡]Eicosapentaenoic acid¬°20­ÓºÒ§t5­ÓÂùÁä¡^¡AEPA¬°À¦¨à¸£³¡µo¨|©Ò»Ý¡BDHA¡]Docosahexanenoic acid¬°22­ÓºÒ§t6­ÓÂùÁä¡^¦³§U©ó½Õ¸`¤ß¦åºÞ¥\¯àªºùÚ©w»P¼vÅT¦å²G¤§¾®¶°¡A¤]¬O²üº¸»X¡]¦p«e¦C¸¢¯À¡^¦X¦¨¤§«eÁͪ«¡C§¡»P¤HÅ餧°·±d»P§K¬Ì¬ÛÃö¡C

¤pÀɮסG¤¤Ãì¯×ªÕ»Ä¡]MCT¡^

¤¤Ãì¯×ªÕ»Ä¡]Medium chain triglycerides, MCT¡^§t¦³6-10­ÓºÒÃ쪺¯×ªÕ»Ä¡A¶i¤J¸z¹D«á¥u»Ý­n20¤ÀÄÁ¡A§Y¥i³Q®ø¤Æ§l¦¬¦Ü²O¤ÚºÞ¦Ü¦å²G¤¤¡A³q±`¥i§@¬°»Ý­n¶i¦æºÞÄé­¹±wªÌªº¯×ªÕ¨Ó·½¡C


°Ñ¦Ò¤åÄm     [top]

1. ¤ý»ñ­^µ¥µÛ¡A¹ê¥ÎÀç¾i¾Ç¡A¥Á°ê88¥Xª© µØÄË¥Xª©ªÀ¡A¥x¥_¥«¡C

2. °ê¤H¿¯­¹Àç¾i¯À°Ñ¦ÒÄá¨ú¶q¤Î¨ä»¡©ú­×­q²Ä¤»ª©¡C¦æ¬F°|½Ã¥Í¸p¡]2003¡^¡C

3. Chanmugam P, Guthrie JF, Cecilio S, Morton JF, Basiotis PP, Anand R. Did fat intake in the United States really decline between 1989--1991 and 1994--1996? J Am Diet Assoc 2003;103:867--72.

4. Whitaker RC, Wright JA, Finch AJ, Psaty BM. An environmental intervention to reduce dietary fat in school lunches. Pediatrics 1993;91(6):1107-11.

5. Freedman DS, Burke GL, Harsha DW, et al. Relationship of changes in obesity to serum lipid and lipoprotein changes in childhood and adolescence. JAMA 1985;254(4):515-20.

6. Kikuchi DA, Srinivasan SR, Harsha DW, Webber LS, Sellers TA, Berenson GS. Relation of serum lipoprotein lipids and apolipoproteins to obesity in children: the Bogalusa Heart Study. Prev Med 1992;21:177-90.

7. Laskarzewski P, Morrison JA, Mellies MJ, et al. Relationships of measurements of body mass to plasma lipoproteins in schoolchildren and adults. Am J Epidemiol 1980;111(4):395-406.

8. Resnicow K, Morabia A. The relation between body mass index and plasma total cholesterol in a multiracial sample of US schoolchildren. Am J Epidemiol 1990;132(6):1083-90.

9. Shear CL, Freedman DS, Burke GL, Harsha DW, Berenson GS. Body fat patterning and blood pressure in children and young adults: the Bogalusa Heart Study. Hypertension 1987;9:236-44.

10. National Heart, Lung, and Blood Institute. Report of the expert panel on population strategies for blood cholesterol reduction. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1990. NIH publication no. 90-3046.

11. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002;160:41¡V8.

12. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. American Journal Cardiology 2002;90:89¡V94.

13. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997;337:1491-1499.

14. Trichopoulo A, Katsouyanni K, Stuver S, et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst. 1995;87:110-116.

15. Decker EA. The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutr Rev 1995;53:49-58.

16. Slesinski MJ, Subar AF, Kahle LL. Dietary intake of fat, fiber and other nutrients is related to the use of vitamin and mineral supplements in the United States: the 1992 National Health Interview Survey. J Nutr 1996;126:3001-3008.

17. Prentice RL. Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research. Breast Cancer Res. 2000;2:268-276.

18. Sigman-Grant M. Can you have your low-fat cake and eat it too? The role of fat-modified products. J Am Diet Assoc. 1997;97:S76-S81.

19. Auld GW, Nitzke SA, McNulty J, Bock MA, Bruhn CM, Gavel K, Lauritzen G, Lee YF, Medeiros D, Newman R, Ortiz M, Read M, Schutz H, Sheehan E. A stage-of-change classification system based on actions and beliefs regarding dietary fat and fiber. Am J Health Promot. 1998;12(3):192-201.

20. Ribaya-Mercado JD. Influence of dietary fat on beta carotene absorption and bioconversion into vitamin A. Nutr Rev 2002;60:104-110.

21. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 1996;126:3032-3039.

22. Ågren JJ, Tormala ML, Nenonen MT, Hanninen OO. Fatty acid composition of erythrocyte, platelet, and serum lipids in strict vegans. Lipids 1995;30:365-369.

23. Krajcovicova-Kudlackova M, Simoncic R, Babinska K, Bederova A. Levels of lipid peroxidation and antioxidants in vegetarians. Eur J Epidemiol 1995;11:207-211.

24. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000;71:179S-188S.

25. Indu, M and Ghafoorunissa. N-3 fatty acids in Indian diets Comparison of the effects of precursor (alpha-linolenic acid) vs. product (long chain n-3 polyunsaturated fatty acids). Nutr Res 1992;12:569-582.

26. Masters C. Omega-3 fatty acids and the peroxisome. Mol Cell Biochem 1996;165:83-93.

27. Pereira C, Li D, Sinclair AJ. The alpha-linolenic acid content of green vegetables commonly available in Australia. Int J Vitam Nutr Res 2001;71:223-228.

28. Burdge GC, Jones AE, Wooton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr 2002;88:355-363.

29. Sanders TAB, Reddy S. The influence of a vegetarian diet on the fatty acid composition of human milk and the essential fatty acid status of the infant. J Pediatr 1992;120:S71-S77.

30. Hornstra G. Essential fatty acids in mothers and their neonates. Am J Clin Nutr 2000;71(suppl):1262S-1269S.

31. Sacks FM, Rouse IL, Stampfer MJ, Bishop LM, Lenherr CF, Walther RJ. Effect of dietary fats and carbohydrate on blood pressure of mildly hypertensive patients. Hypertension 1987;10:452-460.


ºô­¶¡G

1. ¦æ¬F°|°ê®a¬ì¾Ç©e­û·|¬ì¾Ç§Þ³N¸ê®Æ¤¤¤ß
HTTP://WWW.STIC.GOV.TW/

2. ¦æ¬F°|½Ã¥Í¸p¡G­¹«~¸ê°Tºô¡Chttp://food.doh.gov.tw/nutrition/htm

3. °¨°º¬ö©ÀÂå°|Àç¾i½Ò¥þ²yºô¸ô­º­¶
HTTP://WWW2.MMH.ORG.TW/NUTRITION/DDMAIN.HTM

4.¥x¥_ºaÁ`Àç¾i³¡
HTTP://WWW.VGHTPE.GOV.TW/~NUTR/

5. http://www.cdc.gov/mmwr/preview/mmwrhtml/00042446.htm

6. http://www.cfsan.fda.gov/~dms/fdfats.html

¡@